Barclays PLC Acquires 72,448 Shares of COMPASS Pathways plc (NASDAQ:CMPS)

Barclays PLC raised its holdings in shares of COMPASS Pathways plc (NASDAQ:CMPS) by 21.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 413,066 shares of the company’s stock after purchasing an additional 72,448 shares during the quarter. Barclays PLC’s holdings in COMPASS Pathways were worth $3,420,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Oppenheimer & Co. Inc. bought a new stake in shares of COMPASS Pathways during the second quarter worth $86,000. Sumitomo Mitsui Trust Holdings Inc. lifted its position in shares of COMPASS Pathways by 3.2% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 398,335 shares of the company’s stock worth $3,298,000 after purchasing an additional 12,414 shares during the last quarter. TAP Consulting LLC bought a new stake in shares of COMPASS Pathways during the second quarter worth $93,000. Putnam Investments LLC lifted its position in shares of COMPASS Pathways by 41.9% during the first quarter. Putnam Investments LLC now owns 243,863 shares of the company’s stock worth $2,422,000 after purchasing an additional 71,964 shares during the last quarter. Finally, State Street Corp increased its stake in shares of COMPASS Pathways by 534.2% during the first quarter. State Street Corp now owns 104,506 shares of the company’s stock valued at $1,038,000 after buying an additional 88,028 shares during the period. 18.13% of the stock is currently owned by institutional investors.

COMPASS Pathways Price Performance

CMPS opened at $5.27 on Monday. The business’s 50-day moving average is $7.11 and its two-hundred day moving average is $7.98. COMPASS Pathways plc has a 1 year low of $5.22 and a 1 year high of $11.48. The company has a debt-to-equity ratio of 0.12, a current ratio of 18.55 and a quick ratio of 18.55. The firm has a market capitalization of $241.16 million, a PE ratio of -2.03 and a beta of 2.56.

Wall Street Analysts Forecast Growth

CMPS has been the topic of several research reports. HC Wainwright restated a “buy” rating and set a $120.00 price target on shares of COMPASS Pathways in a research note on Friday, August 4th. Canaccord Genuity Group cut their price target on COMPASS Pathways from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, August 22nd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $21.00 price target on shares of COMPASS Pathways in a research note on Thursday, August 17th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $46.83.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.